Navigation Links
Thoratec Comments on February 23rd Voluntary Medical Device Correction Notification
Date:4/4/2012

PLEASANTON, Calif., April 4, 2012  /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR) today commented on a recent voluntary medical device correction notification (the "Notification"), related to the bend relief component for the sealed outflow graft of the HeartMate II® Left Ventricular Assist System.   The company initiated the voluntary Notification to clinicians on February 23, 2012.  

Following the company's voluntary Notification to clinicians on February 23, 2012, the FDA posted information regarding the action on its website during the week of March 19th.  Today, this same information appeared in the news section of the FDA website.  However, today's posting was only a reference to the previous communication, and there was no new information provided. 

After initiating the Notification, Thoratec contacted all hospitals to whom HeartMate II sealed outflow grafts had been distributed.  The company's voluntary Notification was intended to provide information to clinicians, including a clarification of the instructions for use, and did not involve the return of any product.  Subsequently, the company received acknowledgment forms from surgeons at all such U.S. hospitals, verifying that clinicians have reviewed the Notification and understand the information provided. 

Thoratec anticipates no material financial impact from this action. 

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

Many of the preceding paragraphs, particularly but not exclusively those addressing future performance, contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "anticipates," "believes," "views," "expects," "plans," "projects," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Presentation at Leerink Swann Healthcare Conference to be Webcast
2. Thoratec Schedules Fourth Quarter Conference Call, Webcast
3. Thoratec Announces Appointment of William A. Hawkins to Board of Directors
4. Thoratec Presentation at Oppenheimer Conference to Be Webcast
5. Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program
6. Thoratec Reports Third Quarter Fiscal 2011 Results
7. Thoratec Schedules Third Quarter Conference Call, Webcast
8. Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast
9. Thoratec Announces Presentations at Upcoming Investor Conferences
10. Thoratec Reports Second Quarter Revenue Increase of 17 Percent
11. Thoratec Announces Resignation of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... YORK , January 18, 2017 ... of people regarding the use of cannabis both for medical ... only are more Americans open to the use of cannabis, ... financial sectors. According to Arcview Market Research, the North American ... up 30% from the previous year. The research projects sales ...
(Date:1/17/2017)... 2017 Precision medicine is an emerging ... of disease. The approach allows doctors and physicians ... The approach studies the individual profile at a ... In January 2015, Precision Medicine Initiative (PMI) was ... with more than one million volunteers. All of ...
(Date:1/17/2017)... , Jan. 17, 2017 EU5 Glucose Monitoring ... new report, "EU5 Glucose Monitoring Market Outlook to 2022", ... market. The report provides value, in millions of US ... market segments - Blood Glucose Meters, Blood Glucose Test ... shares and distribution shares data for each of these ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone wants ... the best drug option for each patient. Dentists have several general anesthesia alternatives and ... , Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find out ...
(Date:1/17/2017)... ... January 17, 2017 , ... Healthful ... , The company, owned and operated by Ed Stroup, was created to offer ... with the highest level of customer service. Healthful Balance products can be purchased ...
(Date:1/17/2017)... Clemente, CA (PRWEB) , ... January 17, 2017 ... ... Diego County, as well as Palm Desert, is opening a new office in ... Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling ...
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket ... fourth Cradle to Cradle Product Design Challenge , the Cradle to Cradle ... of six circular design challenges scheduled to run through early 2018. The challenges are ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Livionex, Inc., ... results of a double blind clinical study for its dental gel that shows significant ... national brand of toothpaste containing triclosan. The study was conducted at the Beckman Laser ...
Breaking Medicine News(10 mins):